丁型肝炎抗病毒新药研究进展  

Advances in development of new anti-HDV drugs

作　　者：刘玉梅 刘学恩 庄辉 LIU Yu-mei;LIU Xue-en;ZHUANG Hui(Department of Microbiology and Center of Infectious Diseases,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学医学部病原生物学系和感染病中心,北京100191

出　　处：《中国病毒病杂志》2021年第6期414-419,共6页Chinese Journal of Viral Diseases

基　　金：国家“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2018ZX10732401)。

摘　　要：丁型肝炎病毒(hepatitis D virus, HDV)是缺陷病毒,需要在乙型肝炎病毒(hepatitis B virus, HBV)的辅助下才能形成感染。据估计,约5%的HBV感染者合并感染HDV,表现为联合感染(co-infection)或重叠感染(superinfection) 2种形式。慢性丁型肝炎病情严重,疾病进展快,易发展为终末期肝病。干扰素单药或与核苷(酸)类似物(nucleoside/nucleotide analogs, NAs)联合治疗是目前临床治疗慢性丁型肝炎患者的常用方案,但存在持续病毒学应答率低,停药后易复发等问题。近年来,新型抗HDV药物的研发取得了一定进展,主要包括HBV/HDV进入抑制剂——Myrcludex B、法尼酰基转移酶抑制剂——Lonafarnib、HBsAg释放抑制剂—核酸多聚物以及免疫调节剂——Peg-IFNλ。本文就新型抗HDV药物的研究进展作简要综述。Hepatitis D virus(HDV) is a defective RNA virus that requires the help of hepatitis B virus(HBV) to form a complete HDV virion.It is estimated that about 5% of people who infected with HBV are also infected with HDV in the form of co-infection or superinfection.Chronic hepatitis D(CHD) is a severe form of viral hepatitis, which is more likely to develop into advanced liver disease and progresses rapidly.To date, interferon(IFN) as monotherapy or in combination with nucleoside/nucleotide analogs(NAs) is recommended for treatment of HDV infection, but there are problems such as low sustained virological response and high relapse.In recent years, new anti-HDV drugs are under investigation, mainly including viral entry inhibitor-Myrcludex B, the farnesyltransferase inhibitor-Lonafarnib, HBsAg release inhibitors-nucleic acid polymers, and immunomodulator-Peg-IFNλ.The progress of these new anti-HDV drugs is summarized as follow.

关 键 词：肝炎 丁型 丁型肝炎病毒 抗病毒药物 治疗 

分 类 号：R512.64[医药卫生—内科学]